# Contents

## 1 New Drug Development

1.1 Introduction .................................................. 1
1.2 Origin and Goals of the Book .............................. 2
1.3 The Discipline of Statistics ................................. 2
1.4 A Lifecycle Perspective on Drug Development .......... 3
1.5 Design, Conduct, and Analysis ........................... 4
   1.5.1 Compelling Evidence .................................. 4
1.6 Drug Discovery ................................................ 4
1.7 Nonclinical Development Programs ....................... 5
1.8 Clinical Development Programs ............................ 5
   1.8.1 Ethical Conduct ....................................... 6
   1.8.2 Different Studies in a Clinical Development Program ...... 7
1.9 Manufacturing .................................................. 8
1.10 Definitions of Clinical Research and Clinical Trials ... 9
   1.10.1 Clinical Research ................................... 9
   1.10.2 Clinical Trials ...................................... 10
1.11 Operational Execution ...................................... 10
1.12 The Central Importance of Biological Considerations .. 10

## 2 The Regulatory Environment

2.1 Introduction .................................................. 11
2.1.1 Goals of the ICH ....................................... 12
2.2 The Food and Drug Administration ....................... 12
   2.2.1 The Code of Federal Regulations .................... 13
2.3 cGMP, cGLP, and cGCP ...................................... 14
2.4 Regulatory Aspects of New Drug Development .......... 14
2.5 Sponsor and Regulatory Agency Responsibilities ....... 15
2.6 The Investigational New Drug Application .............. 15
   2.6.1 Review of the Investigational New Drug Application ...... 17
2.7 The New Drug Application ........................................... 19
  2.7.1 Statistical Review of the New Drug Application ........ 19
Further Readings ......................................................... 20

3 Drug Discovery .......................................................... 21
  3.1 Introduction ......................................................... 21
    3.1.1 Small Molecule Drug Candidates ......................... 21
    3.1.2 Biopharmaceutical Drug Candidates ..................... 22
  3.2 Overview of Pharmaceutics, Pharmacokinetics,
    and Pharmacodynamics ........................................... 22
    3.2.1 Drug Receptors ............................................... 23
    3.2.2 The Pharmacodynamic Phase .............................. 23
    3.2.3 The Pharmacokinetic Phase ............................... 24
    3.2.4 The Pharmaceutical Phase ................................. 25
  3.3 Medicinal Chemistry ............................................... 25
    3.3.1 Drug Molecules ............................................... 26
    3.3.2 Macromolecules, Receptors, and Drug Targets ......... 26
    3.3.3 Structure–Activity Considerations and
      Drug–Receptor Interactions ................................. 27
  3.4 Cheminformatics, Bioinformatics, and
    Computer-Aided Molecular Design .............................. 28
    3.4.1 Bioinformatics ............................................... 29
  3.5 Biologics .......................................................... 30
    3.5.1 Molecular Genetics and Proteins ......................... 30
    3.5.2 Protein Structures .......................................... 31
    3.5.3 Recombinant DNA Technology ............................ 31
    3.5.4 Recombinant Proteins As Drugs .......................... 32
    3.5.5 Discovery and Development
      of Biopharmaceuticals ....................................... 33
  3.6 Moving to Nonclinical Research ................................. 34
Further Readings ......................................................... 34

4 Nonclinical Research .................................................. 35
  4.1 Introduction ......................................................... 35
    4.1.1 Reduction, Refinement, and Replacement of
      Laboratory Animal Studies ................................... 35
  4.2 Pharmacokinetics .................................................. 36
    4.2.1 Absorption ................................................... 36
    4.2.2 Distribution .................................................. 37
    4.2.3 Metabolism .................................................. 37
    4.2.4 Elimination .................................................. 38
  4.3 Pharmacology ...................................................... 38
    4.3.1 Research Pharmacology Studies .......................... 38
    4.3.2 Safety Pharmacology Studies ............................. 39
  4.4 Toxicological Studies ............................................. 39
    4.4.1 Toxicodynamics ............................................... 40
### 4.4 Exploratory Toxicology Studies
- Pre-FIH Regulatory Toxicology Studies: 40
- Post-FIH Regulatory Toxicology Studies: 41
- Dose Range-Finding Toxicology: 41
- Genotoxicity: 42

### 4.5 Assessment of QT Interval Prolongation
- Long QT Syndrome: Underlying Molecular Biology: 43
- Drug-Induced QT Interval Prolongation: 44
- Associated Nonclinical Testing: 45
- Short QT Syndrome: 45

### Further Readings
- 46

### 5 Designing Clinical Trials
- Introduction: 47
- Classification of Clinical Trials: 47
- Human Pharmacology Trials: 49
- Clinical Pharmacokinetics and Pharmacodynamics: 51
  - Pharmacokinetic Parameters: 52
  - Fasting and Fed Pharmacokinetics: 52
  - Absorption and Bioavailability: 53
  - Distribution: 54
  - Metabolism: 54
  - Elimination/Clearance: 55
- Therapeutic Exploratory Trials: 55
- Therapeutic Confirmatory Trials: 56
- Therapeutic-Use Trials: 56
- Study Design: 56
- Ethical Aspects of Design: 57
- Study Design in Drug Clinical Trials: 57
  - The Parallel Group Design: 58
  - The Cross-over Design: 59
  - Respective Advantages of the Parallel Group and Cross-over Designs: 59
  - Focus on the Parallel Group Design in This Book: 60
- Central Principles of Experimental Design in Clinical Trials: 60
  - Replication: 61
  - Randomization: 61
  - Local Control: 64
  - Good Design Simplifies and Validates the Accompanying Analyses: 64
- Sample Size Estimation: 65
7.8 Monitoring Clinical Trials ........................................ 90
7.9 Data Management .................................................. 91
  7.9.1 Data Management Plans ....................................... 91
  7.9.2 Electronic Data Capture ....................................... 92
  7.9.3 Database Development ....................................... 92
7.10 A New Paradigm: Allying With Sponsors ...................... 93
7.11 Underperforming and Non-performing Clinical Trial Sites ................................................................. 93
  7.11.1 Limitations of the Current Model ......................... 95
7.12 Another New Paradigm: The Site-Specific CRO .............. 95
  7.12.1 Synergies of a Sponsor CRO and a Site-Specific CRO Working Together ........................................ 96
Further Readings ....................................................... 97

8 Statistical Analysis ................................................ 99
8.1 Introduction ......................................................... 99
8.2 Types of Clinical Data ............................................. 100
  8.2.1 Numerical Variables ........................................ 100
  8.2.2 Categorical Variables ....................................... 100
  8.2.3 Parametric Tests and Nonparametric Tests ............... 101
8.3 Descriptive Statistics: Summarizing Data ...................... 101
  8.3.1 Measures of Central Tendency ............................. 101
  8.3.2 Measures of Dispersion Around a Central Value ....... 102
8.4 Inferential Statistics: Hypothesis Testing ...................... 103
  8.4.1 The Search for Compelling Evidence ....................... 103
  8.4.2 Variation and Systematic Variation ....................... 103
  8.4.3 Between-Groups Variation and Within-Groups Variation ................................................................. 104
  8.4.4 Comparing Between-Groups Variance and Within-Groups Variance ............................................. 104
  8.4.5 The Term Error Does Not Imply a Mistake ............... 105
8.5 Probability .......................................................... 105
  8.5.1 Likely Events Do Not Always Happen ....................... 106
  8.5.2 Clinical Decision-Making ................................... 106
  8.5.3 Sampling Theory ............................................ 107
  8.5.4 The Standard Error of the Mean ......................... 107
8.6 The Normal Distribution ......................................... 108
  8.6.1 Area Under the Normal Curve ............................ 110
  8.6.2 Various Areas Under the Normal Curve ................... 111
8.7 Analysis of Association .......................................... 111
  8.7.1 Direction of an Association ............................... 112
  8.7.2 Degree of Closeness of an Association ................... 112
  8.7.3 Correlation Coefficients ................................... 112
  8.7.4 Determining the Significance of a Product Moment Coefficient .................................................... 113
11 Sample Size Estimation

11.1 Introduction

11.2 Ethical Issues in Sample Size Estimation

11.3 Variables Involved in Sample Size Estimation

11.4 Type I and Type II Errors

11.4.1 The Implications of Type I and Type II Errors

11.5 Choosing the Variables Needed for Sample Size Estimation

11.5.1 Alpha and Beta

11.5.2 The Treatment Effect, Its Variance, and the Standardized Treatment Effect

11.6 Using the Appropriate Formula to Yield the Sample Size

11.7 Influences on the Sponsor’s Choice of These Values

11.8 Choosing the Objective(s) on Which to Base the Sample Size Estimation

11.9 Other Issues to Keep in Mind

12 General Safety Assessments

12.1 Introduction

12.2 Operationalizing the Term Drug Safety

12.2.1 Perspectives of Regulators and Prescribing Physicians on Safety Data

12.3 General Safety Assessments

12.3.1 Extent of Exposure

12.3.2 Adverse Events

12.3.3 Common Laboratory Tests

12.3.4 Vital Signs

12.4 Acquisition and Management of Safety Data

12.4.1 Adverse Events

12.4.2 Serious Adverse Event Data

12.5 Analysis Populations

12.6 Presentation of Safety Data

12.6.1 Descriptive Approaches to Safety Data

12.6.2 Time-to-Event Analysis

12.6.3 Differences Between Approaches to Safety and Efficacy Data

Further Readings
<table>
<thead>
<tr>
<th>Section</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>13.2.3</td>
<td>Using Both Analysis Populations</td>
<td>167</td>
</tr>
<tr>
<td>13.2.4</td>
<td>Missing Data</td>
<td>168</td>
</tr>
<tr>
<td>13.3</td>
<td>Hypothesis Testing Is Integral to All of the Designs Discussed</td>
<td>168</td>
</tr>
<tr>
<td>13.4</td>
<td>Superiority Trials</td>
<td>169</td>
</tr>
<tr>
<td>13.4.1</td>
<td>Well-Defined Study Objectives and Endpoints</td>
<td>169</td>
</tr>
<tr>
<td>13.4.2</td>
<td>Analysis of Covariance</td>
<td>170</td>
</tr>
<tr>
<td>13.4.3</td>
<td>Subgroup Analysis</td>
<td>171</td>
</tr>
<tr>
<td>13.5</td>
<td>Equivalence Trials</td>
<td>172</td>
</tr>
<tr>
<td>13.5.1</td>
<td>Why the Hypothesis Testing Strategy Is Different Here</td>
<td>173</td>
</tr>
<tr>
<td>13.5.2</td>
<td>Establishing the Equivalence Margin</td>
<td>174</td>
</tr>
<tr>
<td>13.5.3</td>
<td>Hypothesis Construction and Testing</td>
<td>175</td>
</tr>
<tr>
<td>13.5.4</td>
<td>Statistical Analysis and Clinical Judgment Working Together</td>
<td>176</td>
</tr>
<tr>
<td>13.6</td>
<td>Noninferiority Trials</td>
<td>176</td>
</tr>
<tr>
<td>13.6.1</td>
<td>Establishing the Noninferiority Margin</td>
<td>176</td>
</tr>
<tr>
<td>13.6.2</td>
<td>Hypothesis Construction and Testing</td>
<td>176</td>
</tr>
<tr>
<td>13.6.3</td>
<td>Statistical Analysis and Clinical Judgment Working Together</td>
<td>177</td>
</tr>
<tr>
<td>13.7</td>
<td>Group Sequential Designs</td>
<td>177</td>
</tr>
<tr>
<td>13.7.1</td>
<td>Interim Analyses in Group Sequential Trials</td>
<td>178</td>
</tr>
<tr>
<td>13.7.2</td>
<td>Data Monitoring Committees</td>
<td>178</td>
</tr>
<tr>
<td>13.7.3</td>
<td>Statistical Methodology for Interim Analysis</td>
<td>179</td>
</tr>
<tr>
<td>13.7.4</td>
<td>Ethical Considerations in Early Termination</td>
<td>182</td>
</tr>
<tr>
<td>13.8</td>
<td>Adaptive Designs</td>
<td>183</td>
</tr>
<tr>
<td>13.8.1</td>
<td>Protocol Amendments</td>
<td>183</td>
</tr>
<tr>
<td>13.8.2</td>
<td>Increasing Awareness of Adaptive Designs</td>
<td>184</td>
</tr>
<tr>
<td>13.8.3</td>
<td>Regulatory Guidance for Adaptive Designs</td>
<td>185</td>
</tr>
<tr>
<td>13.9</td>
<td>Bayesian Approaches to Analyzing Clinical Trials</td>
<td>186</td>
</tr>
<tr>
<td>13.10</td>
<td>Meta-analysis</td>
<td>186</td>
</tr>
<tr>
<td>13.10.1</td>
<td>Introduction to Meta-analysis</td>
<td>187</td>
</tr>
<tr>
<td>13.10.2</td>
<td>The Basic Steps</td>
<td>188</td>
</tr>
<tr>
<td>13.10.3</td>
<td>Choice of the Summary Statistic Representing the Treatment Effect of Interest</td>
<td>189</td>
</tr>
<tr>
<td>13.10.4</td>
<td>Data Analysis</td>
<td>189</td>
</tr>
<tr>
<td>13.10.5</td>
<td>Evaluating Robustness</td>
<td>191</td>
</tr>
<tr>
<td>13.10.6</td>
<td>Dissemination of Results and Conclusions of a Meta-analysis</td>
<td>191</td>
</tr>
<tr>
<td>13.11</td>
<td>Therapeutic Use Trials</td>
<td>192</td>
</tr>
<tr>
<td>13.11.1</td>
<td>Large Simple Therapeutic Trials</td>
<td>192</td>
</tr>
</tbody>
</table>

Further Readings | 193 |

14 Cardiac and Cardiovascular Safety Assessments | 195 |
| 14.1 | Introduction | 195 |
| 14.2 | A Three-Component Risk Exclusion Model | 196 |
14.2.1 Confidence Intervals Facilitate the Determination of Thresholds of Regulatory Concern ............................ 197
14.3 Cardiac Safety Assessment: A Brief History ......................... 198
14.4 Obtaining QTc Data from QT Measurements ...................... 199
14.5 The Thorough QT/QTc Study ........................................ 200
14.5.1 Design of the TQT Study ........................................... 200
14.5.2 TQT Study Conduct ................................................... 201
14.5.3 Statistical Analysis .................................................. 202
14.5.4 Ramifications of Interpretations by Sponsors and Regulatory Agencies .................................................. 203
14.6 FDA Guidance on Excluding Unacceptable Cardiovascular Risk in the Development of Antidiabetic Drugs for Type 2 Diabetes Mellitus ......................... 204
14.6.1 Clinical Trials to Be Conducted ..................................... 204
14.6.2 Choice of Subject Populations ...................................... 205
14.6.3 Choice of Cardiovascular Endpoints ................................ 205
14.6.4 Endpoint Adjudication ............................................... 205
14.6.5 The Required Meta-analysis ....................................... 206
14.6.6 A Dedicated Large (Simple) Cardiovascular Trial .............. 207
14.6.7 An Additional Consideration for Safety Meta-analyses ... 208
14.7 An Example of a Real Safety Meta-analysis ......................... 208
14.8 Potential Regulatory Thresholds of Interest for Other Cardiovascular Parameters ........................................ 209
Further Readings ................................................................. 210

15 Manufacturing Small Molecule Drugs and Biologicals .................. 211
15.1 Introduction .................................................................. 211
15.2 Nonclinical Development ................................................ 212
15.3 Drug Products for Clinical Trials ...................................... 212
15.3.1 Need for the Investigative Drug and the Control Drug ...... 213
15.3.2 Blinding of Drug Products for Clinical Trials ............... 213
15.3.3 Packaging and Distributing Clinical Drug Products .......... 214
15.4 Commercial Manufacturing ............................................ 215
15.5 Quality Control: Building Quality into the Process ................ 215
15.6 Stability Studies .......................................................... 216
15.7 Immediate Release and Modified Release Tablets and Capsules .................................................................... 216
15.8 Recombinant Protein Biologicals ....................................... 217
15.8.1 Commercial-Scale Manufacturing ................................ 218
Further Readings ................................................................. 219
16 Postmarketing Surveillance ........................................ 221
  16.1 Introduction .................................................. 221
  16.2 Limitations of Preapproval Clinical Trials .................. 222
  16.3 Individual Differences in Drug Response .................... 223
    16.3.1 Hepatic Impairment ..................................... 223
    16.3.2 Renal Insufficiency .................................... 224
    16.3.3 The Elderly ............................................. 224
    16.3.4 Pediatric Populations ................................... 225
  16.4 Postmarketing Surveillance .................................. 226
  16.5 The 2005 CDER Report to the Nation ......................... 227
  16.6 The Institute of Medicine’s 2006 Report on Drug Safety .... 228
  16.7 The Food and Drug Administration Amendments Act of 2007 ........................................... 229
  16.8 The FDA’s 2008 Sentinel Initiative ......................... 230
    16.8.1 The Science of Safety .................................. 230
    16.8.2 Active Surveillance .................................... 231
Further Readings ....................................................... 231

17 Main Themes and Concluding Comments .......................... 233
  17.1 Introduction .................................................. 233
  17.2 Ethical Considerations ....................................... 234
  17.3 Design, Methodology, Operations, and Analysis .............. 235
    17.3.1 Reducing Bias and Improving Precision ................. 235
    17.3.2 Our Definition of Statistics Revisited ................. 236
    17.3.3 Numerical Representations of Biological Information .... 236
    17.3.4 Some Thoughts on the $p$-Value ......................... 237
  17.4 Confidence Intervals and Clinical Significance .............. 238
  17.5 Pharmacokinetics and Pharmacodynamics ....................... 238
  17.6 Decision-Making ............................................. 239
    17.6.1 The Subjective Nature of Many Decisions ............... 239
    17.6.2 Determining Thresholds of Regulatory Concern ........... 241
  17.7 Benefit–Risk Considerations ................................ 241
  17.8 Biological Considerations Pervade Our Discussions .......... 241
    17.8.1 Biological Underpinnings of Precision Medicine ......... 242
    17.8.2 Pharmacogenetics ....................................... 242
    17.8.3 Pharmacogenomics ...................................... 243
    17.8.4 Pharmacoproteomics .................................... 243
  17.9 Integrated Pharmaceutical Medicine .......................... 244
  17.10 Concluding Comments ........................................ 245

References ............................................................. 247

Index ................................................................. 251
New Drug Development
An Introduction to Clinical Trials: Second Edition
Turner, J.R.
2010, XXV, 256 p., Hardcover